

## E5508 Primary Analysis Clinical Data Description

This data description is for NCT01107626-D1-Dataset.csv. The data in the spreadsheet are the analysis data for the primary manuscript on NSCLC optimal maintenance therapy analysis results, published in

Ramalingam S.S., Dahlberg S.E., Belani C.P., Saltzman J.N., Pennell N.A., Nambudiri G.S., McCann J.C., Winegarden J.D., Kassem M.A., Mohamed M.K., Rothman J.M., Lyss A.P., Horn L., Stinchcombe T.E., Schiller J.H.. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30. PMID: 31361535; PMCID: PMC7001786.

Pemetrexed or bevacizumab is used for maintenance therapy of advanced no squamous non-small cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. This study contains two step registration, induction therapy step and maintenance therapy. All patients who were registered to at least one of the steps are included.

### Data file description

| Field | Name          | Description                             | Coding   |
|-------|---------------|---|--|
| 1     | ID            | De-identified case ID number            | Numeric code, up to 7 digits   |
| 2     | Gender        | Patient's gender                        | 1 = Male<br>2 = Female   |
| 3     | Race          | Patient's race                          | 1 = White<br>3 = Black<br>99 = Other   |
| 4     | Age           | Age at registration                     | Values in years  |
| 5     | Ethnicity     | Patient's ethnicity                     | 1 = Hispanic<br>2 = Not Hispanic<br>-1 = Not reported<br>12 = Unknown  |
| 6     | Reg_step2     | Patient's registration to step 2 status | 2 = registered in step 2   |
| 7     | Treatment     | Assigned Treatment Arm at Step 2        | A = Bevacizumab alone<br>B = Pemetrexed alone<br>C = Combination of Bevacizumab and Pemetrexed<br>NA = Not applicable or Missing |
| 8     | Smoke_history | Patient's smoking history status        | 1 = Current<br>2 = Former<br>3 = Never   |
| 9     | Histology     | Patient's histologic type               | 1 = Squamous Cell Carcinoma<br>2 = Adenocarcinoma<br>3 = Large Cell<br>Undifferentiated  |

|    |                 |  |  |
|----|-----------------|--|--|
|    |                 |  | 4 = Bronchoalveolar Carcinoma<br>5 = Non-small Cell Lung Cancer NOS<br>6 = Other   |
| 10 | Stage           | Patient's disease stage                  | 1 = IIIB<br>2= IV M1a<br>3 = IV M1b<br>4 = Recurrent   |
| 11 | PS              | ECOG Performance status                  | 0 = Fully active, able to carry on all pre-disease performance without restriction (Karnofsky 90-100)<br>1 = Restricted in physically strenuous activity but ambulatory (K 70-80)<br>2 = Ambulatory and capable of all selfcare but unable to carry out any work activities (K 50-60)<br>3 = Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours (K 30-40)<br>4 = Completely disabled (K 10-20) |
| 12 | Response_step2  | Patient's best response for step2        | 1 = Complete response<br>2 = Partial response<br>3 = Stable disease<br>4 = Progressive disease<br>99 = Unevaluable<br>-1 = Unknown   |
| 13 | Response_step1  | Patient's best response for step1        | 1 = Complete response<br>2 = Partial response<br>3 = Stable disease<br>4 = Progressive disease<br>8 = Unevaluable<br>-1 = Unknown  |
| 14 | Weight_loss     | Weight loss in previous six months       | 1 =< 5% of body weight<br>2 = 5-<10% of body weight<br>3 = 10-<20% of body weight<br>4 = ≥ 20% of body weight  |
| 15 | Cva             | History of cerebrovascular accident      | 1 = No<br>2 = Yes  |
| 16 | Prior_surgery   | Patient's prior surgery status           | 1 = No<br>2 = Yes  |
| 17 | Prior_radiation | Patient's prior radiation therapy status | 1 = No<br>2 = Yes  |

|    |                 |   |  |
|----|-----------------|---|--|
| 18 | Os_mos_step2    | Patient's survival time from random assignment                    | Values in month                            |
| 19 | Surv_stat       | Patient's survival status   | 0 = Alive<br>1 = Dead                      |
| 20 | Pfs_mos_step2   | Patient's progression free survival time from random assignment   | Values in month                            |
| 21 | Pfs_stat_step2  | Patient's progression free survival status from random assignment | 0 = No progression<br>1 = Progression/Dead |
| 22 | Os_initial      | Patient's overall survival time from initial registration         | Values in month                            |
| 23 | Os_stat         | Patient's survival status from initial registration               | 0 = Alive<br>1 = Dead                      |
| 24 | Hilar           | Patient's hilar nodes metastatic status                           | 1 = No<br>2 = Yes                          |
| 25 | Mediastinal     | Patient's mediastinal nodes metastatic status                     | 1 = No<br>2 = Yes                          |
| 26 | Contralateral   | Patient's contralateral lung metastatic status                    | 1 = No<br>2 = Yes                          |
| 27 | Pleura          | Patient's pleura metastatic status                                | 1 = No<br>2 = Yes                          |
| 28 | Brain           | Patient's brain metastatic status                                 | 1 = No<br>2 = Yes                          |
| 29 | Skin            | Patient's skin metastatic status                                  | 1 = No<br>2 = Yes                          |
| 30 | Adrenal         | Patient's adrenal metastatic status                               | 1 = No<br>2 = Yes                          |
| 31 | Bone            | Patient's bone metastatic status                                  | 1 = No<br>2 = Yes                          |
| 32 | Liver           | Patient's liver metastatic status                                 | 1 = No<br>2 = Yes                          |
| 33 | Supraclavicular | Patient's Supraclavicular /scalene nodes metastatic status        | 1 = No<br>2 = Yes                          |

|    |                    |   |   |
|----|--------------------|---|---|
| 34 | Ipsilateral        | Patient's Ipsilateral Lung metastatic status        | 1 = No<br>2 = Yes   |
| 35 | Marrow             | Patient's bone marrow metastatic status             | 1 = No<br>2 = Yes   |
| 36 | Other              | Patient's other site metastatic status              | 1 = No<br>2 = Yes   |
| 37 | Cycle_numbers      | Patient's total cycles of having treatment at step2 | Integer   |
| 38 | Reason_offtx_step1 | Patient's off-treatment reason for step 1           | 1 = Treatment completed per protocol criteria<br>2 = Disease progression, relapse during active treatment<br>3 = Adverse event/side effects/complications<br>4 = Death on study<br>5 = Patient withdrawal/refusal after beginning protocol therapy<br>6 = Alternative therapy<br>7 = Patient off treatment for other complicating disease<br>99 = Other |
| 39 | Reason_offtx_step2 | Patient's off-treatment reason for step 2           | 1 = Treatment completed per protocol criteria<br>2 = Disease progression, relapse during active treatment<br>3 = Adverse event/side effects/complications<br>4 = Death on study<br>5 = Patient withdrawal/refusal after beginning protocol therapy<br>6 = Alternative therapy<br>7 = Patient off treatment for other complicating disease<br>99 = Other |

- Metastasis sites were inadvertently mislabeled in the original analysis dataset. The correct metastasis data were provided in the D1 dataset.
- Missing and not applicable values coded -1 for numeric variables, except where noted otherwise.
- In the analysis, months were calculated as  $\text{days}/30.4375$
- Due to data cleaning efforts, data may contain slight discrepancies from that reported in Table 1 and Table 2 in the publication. The number of each metastatic site is incorrect in the publication: The data in this dataset is correct.
- Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).